TNF and pelvic inflammatory disease: Controlling for other potential predictors, individuals with SOT/HSCT had 55% [HR:1.55 (95% CI: 1.15, 2.10)] and PID/SID had 121% [HR: 2.21 (95% CI: 1.70, 2.86)] higher risk of cancer compared to recipients of TNF-i therapy.